Zobrazeno 1 - 10
of 25
pro vyhledávání: '"R. U. Shayakhmetova"'
Autor:
M. N. Starovoitova, O. V. Desinova, L. P. Ananyeva, O. A. Koneva, L. A. Garzanova, O. B. Ovsyannikova, R. U. Shayakhmetova
Publikováno v:
Современная ревматология, Vol 17, Iss 5, Pp 53-60 (2023)
In systemic sclersis (SSc), different types of renal involvement occur. Their severity can range from asymptomatic deterioration of renal function to life-threatening damage, which is a complex therapeutic problem. Rituximab (RTM) has been used in th
Externí odkaz:
https://doaj.org/article/5c9f566b36bd4479822c02a33d3e7a38
Autor:
L. P. Ananyeva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoytova, O. A. Koneva, O. B. Ovsyannikova, S. I. Glukhova, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 485-492 (2023)
Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying effect. This encourages the study of new approaches that potentially affect the fundamental pa
Externí odkaz:
https://doaj.org/article/94e564a8af3f4fdcb29b40b2ffb39302
Autor:
L. A. Garzanova, L. P. Ananyeva, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova, S. I. Glukhova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 2, Pp 199-206 (2023)
Introduction. Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung disease. However, data on tolerability and long-term adverse events (AEs) d
Externí odkaz:
https://doaj.org/article/4bcf1de1ede5431684daf55c292d0355
Autor:
O. B. Ovsyannikova, O. A. Koneva, L. P. Ananieva, L. A. Garzanova, M. N. Srarovoytova, O. V. Desinova, R. U. Shayakhmetova
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 4, Pp 450-454 (2022)
Background. Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc. Predictors of the outcomes of ILD in SSc are under investigation.Objective – to assess association of the digital ulcers with dynamics
Externí odkaz:
https://doaj.org/article/f4fc02c135a1402aa9f573121bf73336
Autor:
O. B. Ovsyannikova, L. P. Ananyeva, O. A. Koneva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoitova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 66-72 (2021)
Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled cl
Externí odkaz:
https://doaj.org/article/6970a796db08439590e7c365a886818c
Autor:
O. B. Ovsyannikova, L. P. Ananyeva, O. A. Koneva, L. A. Garzanova, R. U. Shayakhmetova, O. V. Desinova, M. N. Starovoitova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 91-97 (2020)
Diffuse cutaneous systemic sclerosis (SSc) characterized by an acute, rapidly progressive course and severe damage to the internal organs has an unfavorable prognosis, while the treatment of this often fatal type of the disease has not been sufficien
Externí odkaz:
https://doaj.org/article/b14a6e61fde04e20af5a4f49e5b3fe21
Autor:
R. U. Shayakhmetova, L. P. Ananyeva, O. A. Koneva, M. N Starovoitova, O. V. Desinova, O. B. Ovsyannikova, L. A. Garzanova
Publikováno v:
Современная ревматология, Vol 14, Iss 1, Pp 49-56 (2020)
In anti-U1-ribonucleoprotein (anti-U1-RNP) antibody positive patients with systemic scleroderma (SSD), the clinical picture and course of the disease have specific features: there is a preponderance of its limited form; inflammatory damage to the joi
Externí odkaz:
https://doaj.org/article/d8c78c75aa6542c1b2a396e80c6268f8
Autor:
R. U. Shayakhmetova, L. P. Ananyeva, M. N. Starovoitova, O. V. Desinova, O. A. Koneva, O. B. Ovsyannikova, L. A. Garzanova, M. V. Cherkasova, R. T. Alekperov
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 1, Pp 48-54 (2020)
Various clinical and immunological phenotypes of systemic sclerosis (SS) differ in the frequency and severity of manifestations of the disease, the progression of damage to internal organs, and prognosis. The detection rate of anti-U1-ribonucleoprote
Externí odkaz:
https://doaj.org/article/56c9458eb80046748424290ef5553d6f
Autor:
L. P. Ananyeva, L. A. Garzanova, O. A. Koneva, M. N. Starovoytova, O. V. Desinova, O. B. Ovsyannikova, R. U. Shayakhmetova, M. V. Cherkasova, A. P. Aleksankin, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 1 (2022)
The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANA) and autoantibodies to topoisomerase 1 (anti-Topo 1) in systemic sclerosis (SSc) patients on rituximab (RTX) therapy.Materials and methods. The
Externí odkaz:
https://doaj.org/article/8e773ad2e104498cbd62816d673a14cb
Autor:
R. U. Shayakhmetova, L. P. Ananyeva, O. A. Koneva, M. N. Starovoitova, O. V. Desinova, O. B. Ovsyannikova, L. A. Garzanova
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 5, Pp 539-544 (2019)
Among the patients fulfilling the criteria for systemic sclerosis (SS), there is a subgroup without SS-specific antinuclear antibodies, but positive for anti-ribonucleoprotein (anti-U1 RNP) antibodies. The clinical significance of this type of antinu
Externí odkaz:
https://doaj.org/article/6359d0bff2344c629f0a39c3be43d122